November 9, 2022

The Globe and Mail | AbCellera posts another strong quarter of COVID-19 antibody sales – but new variants could affect 2023 revenue

AbCellera Biologics (NASDAQ: ABCL) Q3 2022 results coverage out now in the Globe and Mail with commentary from Bloom Burton equity research analyst Antonia Borovina:

Click here to read the full article.